Dosage & Administration
| ABC = abacavir, DTG = dolutegravir, 3TC = lamivudine. | ||
Pediatric Population Body Weight | Number of Tablets (once daily) | Recommended Daily Dose |
TRIUMEQ PD Tablets (6 kg to <25 kg) | ||
6 kg to <10 kg | 3 | 180 mg ABC, 15 mg DTG, and 90 mg 3TC |
10 kg to <14 kg | 4 | 240 mg ABC, 20 mg DTG, and 120 mg 3TC |
14 kg to <20 kg | 5 | 300 mg ABC, 25 mg DTG, and 150 mg 3TC |
20 kg to <25 kg | 6 | 360 mg ABC, 30 mg DTG, and 180 mg 3TC |
TRIUMEQ Tablets (≥25 kg) | ||
≥25 kg | 1 | 600 mg ABC, 50 mg DTG, and 300 mg 3TC |
By using PrescriberAI, you agree to the AI Terms of Use.
Triumeq Prescribing Information
Dosage and Administration, | 4/2024 |
Warnings and Precautions, Embryo-Fetal Toxicity | Removed 4/2024 |
TRIUMEQ and TRIUMEQ PD are indicated for the treatment of HIV-1 infection in adults and in pediatric patients aged at least 3 months and weighing at least 6 kg.
TRIUMEQ and TRIUMEQ PD alone are not recommended in patients with resistance‑associated integrase substitutions or clinically suspected integrase strand transfer inhibitor (INSTI) resistance because the dose of dolutegravir in TRIUMEQ and TRIUMEQ PD is insufficient in these subpopulations. See full prescribing information for TIVICAY (dolutegravir).
• Before initiating TRIUMEQ or TRIUMEQ PD, screen for the HLA‑B*5701 allele because TRIUMEQ and TRIUMEQ PD contain abacavir. .• Prior to or when initiating TRIUMEQ or TRIUMEQ PD, test patients for HBV infection.• TRIUMEQ and TRIUMEQ PD may be taken with or without food.• Adults: One tablet of TRIUMEQ daily.
| ABC = abacavir, DTG = dolutegravir, 3TC = lamivudine. | ||
Pediatric Population Body Weight | Number of Tablets (once daily) | Recommended Daily Dose |
TRIUMEQ PD Tablets (6 kg to <25 kg) | ||
6 kg to <10 kg | 3 | 180 mg ABC, 15 mg DTG, and 90 mg 3TC |
10 kg to <14 kg | 4 | 240 mg ABC, 20 mg DTG, and 120 mg 3TC |
14 kg to <20 kg | 5 | 300 mg ABC, 25 mg DTG, and 150 mg 3TC |
20 kg to <25 kg | 6 | 360 mg ABC, 30 mg DTG, and 180 mg 3TC |
TRIUMEQ Tablets (≥25 kg) | ||
≥25 kg | 1 | 600 mg ABC, 50 mg DTG, and 300 mg 3TC |
• Do not substitute TRIUMEQ and TRIUMEQ PD on a milligram-per-milligram basis.• If dosing with certain UGT1A or CYP3A inducers, then the recommended dolutegravir dosage regimen should be adjusted. See Table 2 for complete dosing recommendations.• Because TRIUMEQ and TRIUMEQ PD are fixed-dose tablets and cannot be dose adjusted, TRIUMEQ and TRIUMEQ PD are not recommended in patients with creatinine clearance <30 mL/min and pediatric patients with a similar degree of renal impairment based on age-appropriate assessment of renal function, or patients with hepatic impairment.
TRIUMEQ tablets are purple, biconvex, oval, and debossed with “572 Trı” on one side. Each film-coated tablet contains 600 mg of abacavir (as abacavir sulfate), 50 mg of dolutegravir (as dolutegravir sodium), and 300 mg of lamivudine
TRIUMEQ PD tablets for oral suspension are yellow, capsule-shaped, strawberry cream flavored, biconvex, film-coated tablets debossed with “SV WTU” on one side. Each film-coated tablet contains 60 mg of abacavir (as abacavir sulfate), 5 mg of dolutegravir (as dolutegravir sodium), and 30 mg of lamivudine
• Pediatrics: Not recommended for patients aged <3 months or weighing <6 kg.• TRIUMEQ and TRIUMEQ PD are not recommended in patients with creatinine clearance less than 30 mL/min and pediatric patients with a similar degree of renal impairment based on age-appropriate assessment of renal function.• If a dose reduction of abacavir, a component of TRIUMEQ and TRIUMEQ PD, is required for patients with mild hepatic impairment, then the individual components should be used.